title: Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.
abstract: Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.
authors.affiliation: Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland.
authors.forename: Philipp
authors.initials: P
authors.lastname: Müller
authors.affiliation: Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland.
authors.forename: Kea
authors.initials: K
authors.lastname: Martin
authors.affiliation: Department I of Internal Medicine and Cologne Interventional Immunology; University Hospital Cologne ; Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Theurich
authors.affiliation: Department I of Internal Medicine and Cologne Interventional Immunology; University Hospital Cologne ; Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: von Bergwelt-Baildon
authors.affiliation: Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland ; Department of Medical Oncology; University Hospital Basel ; Switzerland.
authors.forename: Alfred
authors.initials: A
authors.lastname: Zippelius
keywords: DC maturation; T cells; anti-tumor immunity; antibody-drug conjugates; cancer; immune response; microtubule-depolymerizing chemotherapy